Strong interest in AI-assisted peptide drug discovery and integrated CRDMO services positions the Swiss innovator for expansion in North America
San Diego, California – Space Peptides successfully concluded a highly productive participation at the BIO International Convention 2026, held in San Diego from June 22–25. As the world’s largest biotechnology partnering event, BIO International brought together more than 10,000 life science professionals representing over 5,300 companies from around the globe, providing an exceptional platform for strategic partnerships and business development.
Exhibiting within the Swiss Biotech Pavilion, Space Peptides showcased its integrated portfolio spanning AI-assisted peptide drug discovery, peptide process development, and end-to-end CRDMO services. The convention marked an important milestone in the company’s strategic expansion into the United States, generating numerous high-quality discussions with biotechnology innovators, pharmaceutical companies, investors, and potential strategic partners.
Throughout the four-day event, Space Peptides held a broad range of partnering meetings with companies active in oncology, neuroscience, metabolic diseases, inflammatory disorders, drug delivery, biologics, and advanced therapeutics. Interest focused particularly on the company’s AI-driven computational peptide drug discovery platform, custom peptide libraries, GMP peptide manufacturing capabilities, peptide nucleic acids (PNAs), and integrated development services extending from early discovery through commercial manufacturing. Several discussions have already progressed into technical follow-up meetings and business development activities. The breadth and quality of customer interactions demonstrated the growing demand for integrated peptide innovation platforms capable of combining advanced computational drug discovery with world-class development and manufacturing expertise. The event also created opportunities to establish new strategic relationships with pharmaceutical companies, emerging biotechnology firms, technology developers, and complementary CRDMO partners across North America and internationally.
The company’s growing international profile was further highlighted by a visit to the Swiss Pavilion by Minnesota’s Governor Tim Walz, providing an opportunity to present Switzerland’s role as a frontrunner within the Biotech community and to discuss the importance of international collaboration in advancing the biotechnology industry.
“BIO International Convention is where the global biotechnology industry comes together to create tomorrow’s partnerships,” said Dr. Josef Schröer, Chief Commercial Officer of Space Peptides. “The outstanding response to our AI-assisted peptide drug discovery platform and our integrated CRDMO capabilities confirms that the market is looking for partners who can seamlessly bridge computational innovation with world-class peptide development and GMP manufacturing. The quality of the discussions we had in San Diego significantly strengthens our confidence in the U.S. market and represents an important milestone in building Space Peptides’ North American presence.”
Following the convention, Space Peptides will advance multiple commercial discussions initiated during BIO while continuing to expand its business development activities in the United States. Building on its recent successful regulatory inspection for EU market access and its growing global footprint, the company remains committed to becoming a leading international partner for peptide therapeutics—from AI-assisted discovery through clinical and commercial manufacturing.